Is the Potential of Psychedelic Stocks an Illusion?

Someone should do a study that explores how many cannabis investors smoke cannabis. To truly appreciate the potential, you probably need to understand the product. Similarly, one wonders how many investors in psychedelic stocks understand the potential because they’ve experienced just how profoundly moving an acid trip is, or how much darn fun mushrooms can be, or how surreal it is to explore a k-hole and battle demons. Only if you’ve dabbled in psychedelics can you truly appreciate their potential in therapeutics.

Some investors like “Shark Tank” judge Kevin O’Leary believe the potential for psychedelic therapeutics is a once-in-a-lifetime opportunity worth “hundreds of billions of dollars,” a total addressable market (TAM) that far exceeds the cannabis opportunity. It’s bold claims like this that led us to investigate 7 Psychedelic Therapy Companies Addressing Mental Health several years ago, some of which are now public. In fact, enough public companies dabble in psychedelic therapeutics that four ETF providers have now launched thematic ETFs, none of which have attracted meaningful assets under management (AUM). The largest of these by AUM – the Horizons Psychedelic Stock Index ETF (PSYK.NE) – has only managed to attract about $18 million USD. Below you